Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus dolutegravir as a two-drug regimen in adults naive to antiretroviral therapy (DYNAMIC): 24-week results from a randomised phase 2b study.

ABSTRACT:

Background

There is an unmet need for two-drug antiretroviral regimens with novel mechanisms of action that can provide additional options for people with HIV-1. The DYNAMIC study evaluated the efficacy and safety of the maturation inhibitor GSK3640254 (GSK'254) plus dolutegravir (DTG) in adults naive to antiretroviral therapy.

Methods

This double-blind, multicentre, phase 2b study enrolled participants from 39 centres in ten countries (Argentina, Canada, France, Germany, Italy, Portugal, Puerto Rico, South Africa, Spain, and the United States). Eligible participants were adults with plasma HIV-1 RNA ≥1000 copies/mL and CD4+ T-cell count ≥250 cells/mm³ who were naive to antiretroviral therapy. Participants were centrally randomised to receive once-daily oral GSK'2

SUBMITTER: Joshi SR 

PROVIDER: S-EPMC12675015 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature